Press Releases TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.86 ^USD	+2.76%		-15.45%	-73.50%

Apr. 30	TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	MT
Apr. 29	TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update	May. 14	AQ
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering	Apr. 29	AQ
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting	Apr. 29	AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	Apr. 16	AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	Apr. 15	AQ
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 28	AQ
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs	Mar. 27	AQ
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	Mar. 25	AQ
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	Mar. 20	AQ
TFF Pharmaceuticals Announces Update on Clinical Programs	Mar. 20	AQ
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024	Mar. 14	AQ
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference	Jan. 24	AQ
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	Jan. 09	AQ
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC	Dec. 19	AQ
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC	Dec. 18	AQ
TFF Pharmaceuticals Announces Reverse Stock Split	Dec. 15	AQ
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors	Dec. 13	AQ
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors	Nov. 30	AQ
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors	Nov. 30	AQ
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023	Nov. 27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Press Releases

Filters